Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline (Q34603644)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
scientific article

    Statements

    Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline (English)
    Michael W Schuster
    Dina Ben-Yehuda
    Anthony L Boral
    Anthony A Amato
    16 January 2009

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit